Skip to main content
OpenTrials
Completed

NCT Number: NCT01716169

Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care

The purpose of this study is to test the effectiveness of Helicoll (a collagen wound dressing) in treating chronic and non-chronic wounds of recessive dystrophic epidermolysis bullosa (RDEB) patients. Helicoll will be compared to standard wound dressings.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Written consent must be obtained from subjects over age 18, or from a parent or legally authorized representative if subject is under 18. Assent will be obtained from subjects age 7 - 17.
  • Subjects with a clinical diagnosis of RDEB by a dermatologist.
  • Have at least three target wounds that meet the following criteria:
  • One chronic wound, of approximately 6 months or more duration. If the subject has an additional chronic wound of similar size and duration, this additional wound will be treated with standard dressings and followed in the study. A wound in an area that consistently heals and then breaks down again will be considered a chronic wound.
  • Two non-chronic wounds, of approximately 3 months or less duration, of similar size, and able to be dressed separately. Both wounds should have approximately the same duration.

All wounds must be:

  • Open, and not scabbed or crusted over
  • Not actively infected
  • Not requiring surgical intervention
  • A parent or legally authorized representative must be willing and able to ensure subject is present for all required study visits (for minor subjects).
  • The subject or caregiver (or a parent or legally authorized representative for subjects under 18) must be able to follow instructions.
  • Subject must be age 7 or older.

Exclusion criteria

  • Inability to travel to Stanford for study visits.
  • Complicating illness as determined by study investigators to be exclusionary including any infection requiring systemic antibiotics.
  • Presence or history of squamous cell carcinoma at target wound site.
  • Known bovine (cow) or ovine (sheep) sensitivity.
  • Therapy with an investigational agent during the study.

Treatment and study plan

Helicoll

Device

Helicoll Collagen I Wound Dressing

Standard of Care Dressings

Device

Standard of Care wound dressings (e.g. Vaseline gauze)

Primary outcomes

  1. Percentage of Wound Surface Area Change From Baseline to Week 8

    Time frame: Baseline and Week 8

    Change was assessed in terms of wound surface area, as measured using the ARANZ camera. Week 8 surface area measurement was compared to baseline surface area measurement and percentage in size change was calculated.

Sponsors and collaborators

Lead sponsor

Stanford University

Other

Registry information

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Oct 29, 2012
Registry last updated
May 5, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.